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Abstract
Objective: To estimate the prevalence of drug-resistant tuberculosis (TB) and describe the resistance patterns in patients
commencing antiretroviral therapy (ART) in an HIV clinic in Durban, South Africa.
Design: Cross-sectional cohort study.
Methods: Consecutive HIV-infected adults ($18y/o) initiating HIV care were enrolled from May 2007–May 2008, regardless
of signs or symptoms of active TB. Prior TB history and current TB treatment status were self-reported. Subjects
expectorated sputum for culture (MGIT liquid and 7H11 solid medium). Positive cultures were tested for susceptibility to
first- and second-line anti-tuberculous drugs. The prevalence of drug-resistant TB, stratified by prior TB history and current
TB treatment status, was assessed.
Results: 1,035 subjects had complete culture results. Median CD4 count was 92/ml (IQR 42–150/ml). 267 subjects (26%)
reported a prior history of TB and 210 (20%) were receiving TB treatment at enrollment; 191 (18%) subjects had positive
sputum cultures, among whom the estimated prevalence of resistance to any antituberculous drug was 7.4% (95% CI 4.0–
12.4). Among those with prior TB, the prevalence of resistance was 15.4% (95% CI 5.9–30.5) compared to 5.2% (95% CI 2.1–
8.9) among those with no prior TB. 5.1% (95% CI 2.4–9.5) had rifampin or rifampin plus INH resistance.
Conclusions: The prevalence of TB resistance to at least one drug was 7.4% among adults with positive TB cultures initiating
ART in Durban, South Africa, with 5.1% having rifampin or rifampin plus INH resistance. Improved tools for diagnosing TB
and drug resistance are urgently needed in areas of high HIV/TB prevalence.
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Introduction
Infection with tuberculosis (TB) remains the leading cause of
mortality among HIV-infected people worldwide [1]. South Africa
has the third highest TB incidence in the world, with ,1,000 cases
per 100,000 people per year and the most HIV-infected citizens of
any country [2,3]. Even for people successfully diagnosed with TB
in South Africa, TB treatment completion remains a challenge. In
PLOS ONE | www.plosone.org 1 August 2012 | Volume 7 | Issue 8 | e432812005, KwaZulu-Natal, the South African province with the
highest HIV prevalence, reported the greatest number of smear-
positive pulmonary TB cases in the country and had the lowest
cure rate (45%) [4]. The emergence of drug-resistant TB, which is
challenging to diagnose and treat, threatens to undo the progress
made in HIV treatment and care within an overburdened public
health infrastructure in South Africa [5,6].
In 2005, a substantial burden of multi-drug (MDR) and
extensively-drug resistant (XDR) TB was identified among HIV-
infected patients in the rural Msinga District of KwaZulu-Natal.
Enhanced surveillance there revealed 39% MDR TB and 6%
XDR TB among HIV-infected patients with culture-confirmed
TB, exceeding previous surveys [7]. However, province-wide
surveillance in KwaZulu-Natal has largely reflected sputum
cultures performed on request based on clinical suspicion of
treatment failure. This practice has varied widely among districts,
with an estimated 80% of reported cases lacking culture
confirmation and drug susceptibility testing [8,9]. In addition,
individual-level data, such as prior TB treatment exposure and
HIV status, have not been available in population-based surveys of
TB drug resistance.
In the setting of an intensive TB screening program using
mycobacterial culture and drug susceptibility testing for all
patients, our objective was to assess the prevalence of drug-
resistant TB and to describe the resistance patterns in TB culture
positive patients commencing ART in an urban HIV clinic in
Durban, South Africa.
Methods
We evaluated disease prevalence and drug resistance patterns
through an intensive TB screening program for HIV-infected
patients starting antiretroviral therapy in Durban, South Africa.
The Sinikithemba HIV clinic, based at McCord Hospital, a semi-
private urban hospital in Durban, has been offering ART since
1999. McCord Hospital is a 142-bed state-aided (public/private
partnership) general hospital that serves a mainly urban popula-
tion from the greater Durban area, as well as more distant parts of
KwaZulu-Natal. In 2004, the clinic became a U.S. President’s
Emergency Plan for AIDS Relief-funded site and subsequently
initiated ART in over 8,000 patients. During the study period, the
clinic provided ART literacy training to HIV-infected patients
with CD4 counts ,200/ml, those who met clinical criteria (WHO
stage 3 or 4 disease), and patients who were transferring their care
to Sinikithemba [10]. McCord charges subsidized fees for services;
during the study period, patients paid an all-inclusive 90 ZAR (12
USD 2008) monthly fee for HIV care. Patients diagnosed with TB
at Sinikithemba were offered TB treatment on-site, with fixed-dose
regimens according to South African treatment guidelines [11].
The enrollment procedure for the study population has been
previously described [12]. Briefly, for one year beginning in May
2007, a convenience sample of consecutive HIV-infected adults
($18 years) attending ART literacy training were offered enroll-
ment into this prospective cohort study, regardless of signs or
symptoms of active TB. Patients taking TB treatment at
enrollment and/or already taking ART who were newly trans-
ferring their care to Sinikithemba were also eligible. A trained
research nurse obtained written consent, and then administered
a 12-item questionnaire that included demographic data as well as
self-reported history of prior TB infection and current TB
treatment status. All patients expectorated a single sputum
specimen, either spontaneously or using ultrasonic nebulization
if needed, with single-use tubing to avoid contamination Samples
were transported daily to the collaborative TB laboratory of the
University of KwaZulu-Natal and the South African Medical
Research Council in Durban.
Sputum specimens were processed for Mycobacterium tuberculosis
culture (Middlebrook 7H11 solid agar medium and BACTEC
mycobacterial growth indicator tube [MGIT] 960 System; BD).
TB was confirmed in positive solid or MGIT liquid cultures
containing acid fast bacilli using niacin and nitrate testing. Positive
cultures were subcultured on quadrant 7H10 agar for susceptibility
testing using the 1% proportional method. Isolates were tested for
susceptibility to isoniazid, rifampin, streptomycin, ethambutol,
ofloxacin, and kanamycin. Handling of sputum samples adhered
to good microbiological practice with all sample manipulation
being performed in a class II biosafety cabinet. Manipulation of
each sample was completed before the next sample was
manipulated. Sputum samples were decontaminated and pro-
cessed in ‘‘batches’’ of a maximum of 10 samples, plus two freshly
created standardised controls (H37Rv - positive and E.coli -
negative) as well as reagent controls with each batch. Ten percent
of all smears were quality controlled, and all smear-negative
samples were checked by a second microscopist. A drug
susceptible strain (H37Rv) and a drug resistant strain (A169) were
included with each batch of susceptibilities and with each new
media manufacture. All drug resistant results were confirmed by
a second reader and were retested to confirm the resistance
pattern. We evaluated the prevalence of drug-resistant TB,
stratified by prior TB history and current TB treatment status,
with 95% confidence intervals calculated using the binomial
distribution.
The study was approved by the McCord Hospital Research
Ethics Committee (Durban, South Africa) and the Partners
Human Research Committee (protocol 2007-P-000228; Boston,
Massachusetts, USA).
Results
One thousand thirty-five patients were enrolled for whom
sputum culture was carried out, representing approximately 90%
of patients commencing ART literacy training during the study
period. The median CD4 count was 92/ml (IQR 42–150/ml).
Nebulized sputum induction was required in 167 patients (16%).
Two-hundred sixty-seven patients (26%) reported a prior history
of TB and 210 patients (20%) were receiving TB treatment at the
time of enrollment. Forty-seven (22%) of those receiving TB
treatment at enrollment reported a prior history of TB.
Sputum cultures were positive for M. tuberculosis in 191 (18%)
patients, of which 175 (92%) had susceptibility data available.
Patients with TB resistant to any drug (n=13) were similar to
patients with fully susceptible positive TB sputum cultures
(N=178) with regards to age, gender, employment status, previous
hospitalization, household members with TB, and stage of HIV
disease (Table 1). The median CD4 count among patients with TB
resistant to any drug at the time of study enrollment (48 cells/ml,
IQR 26–82 cells/ml) was lower than the median for patients with
fully susceptible TB (79 cells/ml, IQR 41–131 cells/ml; p=0.06).
Forty-six percent of patients with drug-resistant TB reported
a prior history of TB, compared with 22% of patients with fully
susceptible TB (p=0.05).
The prevalence of resistance to any anti-tuberculous drug was
7.4% (95% CI 4.0–12.4; Figure 1, speckled bar). Among patients
on TB treatment at enrollment, the prevalence of drug-resistant
TB was 9.1% (95% CI 0.2–41.3) in those with prior history of TB
compared to 12.5% (95% CI 1.5–38.4) in those reporting no prior
TB (p=0.78). In patients not on TB treatment at enrollment, the
prevalence of drug-resistant TB was 17.9% (95% CI 6.1–36.9) in
Drug-Resistant Tuberculosis in South Africa
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prior TB (p=0.009). In total, among those with prior history of
TB treatment, the prevalence of drug resistance was 15.4% (95%
CI 5.9–30.5), compared to 5.2% (95% CI 2.1–10.3) among those
with no prior history of TB (p=0.032).
The overall prevalence of rifampin or rifampin plus isoniazid
resistance (multi-drug resistant or MDR-TB) was 5.1% (95% CI
2.4–9.5). Among patients receiving TB treatment at enrollment,
the prevalence of rifampin or MDR-TB was 9.1% (95% CI 0.2–
41.3) in those with prior TB compared to 12.5% (95% CI 1.6–
38.4) in those reporting no prior TB (p=0.78). In patients not
receiving TB treatment at enrollment, the prevalence of rifampin
or MDR-TB was 10.7% (95% CI 2.3–28.2) in those with prior TB
versus 2.5% (95% CI 0.5–7.1) in those with no prior TB (p=0.04).
Among those with prior history of TB treatment, the prevalence of
rifampin or MDR-TB was 10.3% (95% CI 2.9–24.2), compared to
3.7% (95% CI 1.2–8.4) in those with no prior history of TB
(p=0.10).
The overall prevalence of streptomycin resistance was 2.9%
(95% CI 0.9–6.5). Subjects with a prior history of TB had a 10.3%
(95% CI 2.9–24.2) prevalence of streptomycin resistance,
compared to 0.7% (95% CI 0.02–4.0) among subjects without
a prior TB history (p=0.002).
Table 1. Baseline characteristics of all patients with tuberculosis and patients with tuberculosis resistant to any drug, according to
culture and sensitivity testing, in an HIV clinic in Durban, South Africa, 2007–2008.
Characteristic
Patients with tuberculosis,
total (N=191)
Patients with drug susceptible
tuberculosis
{ (N=178)
Patients with tuberculosis
resistant to any drug (N=13)
Demographic characteristics (%)
Female 99 (52) 92 (52) 7 (54)
Age, median (years) 36 (31–43) 36 (31–43) 43 (32–45)
Employed 104 (55) 98 (56) 6 (46)
HIV-related characteristics (%)
Baseline CD4 count, median cells/ml (IQR) 78 (40–125) 79 (41–131) 48 (26–82)
WHO stage 3 or 4 disease 136 (84) 127 (84) 9 (90)
On ART at study entry* 17 (9) 16 (9) 1 (8)
Other clinical characteristics (%)
Prior history of tuberculosis 46 (24) 40 (22) 6 (46)
Household member with history of tuberculosis 43 (23) 39 (22) 4 (31)
Hospitalized in previous 5 years 38 (23) 36 (24) 2 (18)
*A small proportion of patients undergoing HIV literacy training had previously started ART.
{Includes patients missing drug susceptibility data and with partial susceptibility data without evidence of resistance.
doi:10.1371/journal.pone.0043281.t001
Figure 1. Prevalence of resistance to any drug (%), stratified by treatment status. Error bars represent 95% confidence intervals.
doi:10.1371/journal.pone.0043281.g001
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resistance to isoniazid, rifampin, and streptomycin. One subject
without prior history of TB had resistance to kanamycin alone. No
ofloxacin resistance was detected.
Results of sensitivities to first- and second-line anti-TB drugs
were not available for all sputum cultures. Of the 191 patients with
positive cultures, 2 had partial sensitivity data and 16 had no
sensitivity data available. Compared to the 173 patients with
complete sensitivity data, these 18 patients were older (median age
41 versus 36 years, p=0.01) and had lower median CD4 counts at
baseline (46/mL versus 80/mL, p=0.04).
Discussion
We report the prevalence of TB resistance to any anti-TB agent
to be 7.4% (95% CI 4.0–12.4) among sputum culture positive
patients initiating ART and intensively screened for TB in
Durban, South Africa. Our data are consistent with the WHO
South African estimate of 7.9% for any drug resistance among
reported TB cases [13]. We found a high prevalence of rifampin
resistance and MDR-TB, with a prevalence of 10.3% (2.9–24.2%)
in patients previously treated for TB. MDR-TB has been
associated with poor short-term outcomes among HIV-infected
people in South Africa [14]. The scale-up of Xpert MTB/RIF
screening in South Africa will allow for a more expedient diagnosis
of rifampin-resistant TB and may improve TB outcomes by
shortening diagnostic delays and ineffective initial therapy [15].
As observed in Tugela Ferry, a substantial proportion of
patients with no prior history of TB had evidence of drug
resistance. Of 13 patients with drug resistant TB, 5 (38%) had no
prior history of TB and were not on TB treatment at enrollment.
While prior TB treatment data are based on self-report, these
results are consistent with data from Tugela Ferry showing that
HIV-infected patients not previously treated for TB are at risk for
exogenous infection with drug-resistant mycobacteria (primary
resistance) [16]. In addition, we found high rates of streptomycin
resistance among patients with a prior history of TB 10.3% (95%
CI 2.9–24.2), calling into question the currently recommended TB
retreatment strategy of adding streptomycin, a single agent, to the
standard 4-drug TB induction regimen. [17,18].
No cases of XDR-TB were found during the study period. This
is in contrast to the high rates of XDR-TB seen among HIV-
infected patients in the Msinga District (Tugela Ferry), also in the
province of KwaZulu-Natal [7]. Despite close proximity between
Tugela Ferry and Durban, there were differences between the site
(rural provincial hospital versus semi-private urban hospital) and
study population (inpatient and ambulatory versus ambulatory
only). To what degree such environmental disparities or other
treatment-related factors explain the difference in prevalence is
uncertain.
There are several limitations to this study. Because McCord
Hospital is a semi-private institution, patients presenting for
treatment have the capacity to pay a small co-payment fee for the
care received; the study sample may not be fully generalizable to
the larger South African population. They may differ from those
who receive care free of charge at governmental Department of
Health clinics. Our study also focused solely on ambulatory
patients. It is possible that inpatients at McCord Hospital have
different resistance patterns than were observed here. However,
because patients reported their previous 5 years of hospitaliza-
tions, where exposure rates are high, we believe that the patterns
would not be markedly different. We do not have information
regarding prior TB treatment regimens or completion. We are
likely to have underestimated the overall prevalence of TB, as well
as drug-resistant TB, because of the use of a single sputum culture
for pulmonary TB diagnosis [12]. Additionally, not all sputum
cultures had full sensitivity data available; our results may
underestimate the true prevalence of drug-resistance.
Given the potential for acquisition of primary TB drug
resistance among HIV-infected patients and worse outcomes for
those infected with drug-resistant TB, this study argues in favor of
improving infection control measures in the healthcare setting to
minimize transmission of TB. Such measures, as well widespread
implementation of rapid and accurate tools for diagnosing both
TB and drug resistance in areas of high HIV/TB prevalence, are
urgently needed.
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